Novavax Inc. (NVAX)

Novavax's stock fell 6.34% in the latest session to $10.20, on volume 102.8% above its average, and it now sits 3.84% below its 50-day average while holding above its 200-day average. The move comes after a quarter in which the company beat analysts' loss estimate and the shares rose 10.22% in the next session.

The shares rose 10.22% in the first session after the November 5, 2026 report, when Novavax posted EPS of -$0.19 against an analyst estimate of -$0.35, a beat of 45.71%. That was the company's second straight beat and its loss was narrower than expected. The stock has since given back ground, falling 6.34% in the latest session, on volume 102.8% above average. Over one month the shares are down 20.00%, while over one year they are up 43.46%.

Novavax has beaten the EPS estimate in six of its last seven reports, but the price reaction has been mixed: in three of those six beats the shares closed lower in the first session. The May 6, 2026 beat was the largest, at 75.00%, yet the stock fell 1.39% the next day. A beat tells investors the loss came in smaller than the forecast, not that the business is growing. Analysts expect fiscal 2026 EPS of $0.05 and revenue of $466.4M, which would be a 58.5% revenue decline, so the forecasts themselves show a shrinking top line.

Five of nine analysts rate the stock Buy or Strong Buy, one rates it Hold and three rate it Sell. B. Riley Securities kept its Buy rating on November 6, 2026, while Citigroup kept its Sell rating on October 15, 2026. Three months ago the Buy count was also five of nine, so the split has not shifted much. CleaRank's rating of Hold, at 44/100, is more cautious than the Buy consensus, mainly because valuation and growth weigh against the stock.

The base case is that NVAX keeps trading between its 200-day average and its 50-day average while investors wait for evidence that the beat on November 5, 2026 is part of a lasting improvement. Analysts' full-year 2026 EPS estimate of $0.05 implies a sharp swing from the reported loss, and the 2027 estimate of -$0.26 shows losses are expected to continue. Conditions that would improve the picture include the price reclaiming the 50-day average and holding it, and revenue growth returning. Conditions that would worsen it include a close below the 200-day average, which has not yet happened, and further estimate cuts. The median analyst target is $16.00, with a range from $7.00 to $25.00, so the spread of views is wide.

Support sits first at the 200-day simple moving average of $9.34, which the price has held above. Below it, the 52-week low of $6.20 is the next floor and marks the bottom of the past year's range. Resistance begins at the 20-day exponential moving average of $10.48, a short-term trend line the price has just dropped below. Next is the 50-day simple moving average at $10.61, which is the level that matters most for the medium-term trend. Further above, the 52-week high of $13.39 is the ceiling of the past year.